On June 5-7, 2014 in San Francisco, CA, the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation presented the 4th Biennial Epilepsy Pipeline Conference 2014, held at the Hyatt Regency, San Francisco.

Showcasing the most promising epilepsy therapies from healthcare companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy and seizures, this year's conference featured the third annual "Shark Tank" competition, in addition to a day designated for people with epilepsy, families and advocates. The conference brought together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation and product development. Speakers and attendees included emerging biotech and medical technology companies, major pharmaceutical and device companies, and researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.

  • SESSION I: Introduction and Keynote Address by Phillip Gattone, CEO and President, Epilepsy Foundation
  • SESSION II: What was better in 2013 than 2012 -- Progress in Epilepsy Therapy, moderated by Jacqueline French, MD, Professor of Neurology, New York University
  • SESSION III: Early-Stage Drug Pipeline: Proof of Principle through IND. Moderated by Roger J. Porter, MD, Chief Scientific Officer, Epilepsy Foundation
  • SESSION IV: Early-Stage Diagnostic Devices and Product Pipeline: New Concepts and Initial Findings, moderated by Daniel Friedman, MD, Assistant Professor of Neurology, New York University
  • SESSION V: Late-Stage and Approved Devices--What is New? moderated by, Daniel Friedman, MD, Assistant Professor of Neurology, New York University
  • SESSION VI: Nonprofit Organization, Government and Crowdfunding--Grants, Awards and Funding to Advance Research to the Next Critical Stage, moderated by Roger J. Porter, MD, Chief Scientific Officer, Epilepsy Foundation.
  • Lifetime Accelerator Award: Honoring H. Steve White, PhD
  • SESSION VII: New Directions and Opportunities in Epilepsy Research, moderated by Jacqueline French, MD, Professor of Neurology, New York University
  • SESSION VIII: Clinical Stage Drugs, moderated by Steven C. Schachter, MD, Professor of Neurology, Harvard Medical School, Chief Academic Officer, Consortia for Improving Medicine with Innovation and Technology
  • SESSION IX: Who is Investing in Epilepsy and CNS Therapy Research and Innovation Today? Funding Beyond Angels, Grants and Awards, moderated by Casey Lynch, Managing Director, NeuroInsights, LLC, Neurotechnology Industry Organization (NIO), CEO, Cortexyme, Inc.
  • Shark Tank Competition, moderated by Jacqueline French, MD.
  • Closing Remarks by Philip Gattone, President and CEO, Epilepsy Foundation
ADVERTISEMENT
ADVERTISEMENT